ZA200603681B - Interleukin-10 antibodies - Google Patents

Interleukin-10 antibodies

Info

Publication number: ZA200603681B
Authority: ZA; South Africa
Prior art keywords: interleukin; antibodies
Prior art date: 2003-11-10

Application number

ZA200603681A

Other languages

English (en)

Inventor

Leonard G Presta

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-10

Filing date

2006-05-09

Publication date

2010-01-27

2006-05-09 Application filed by Schering Corp filed Critical Schering Corp

2010-01-27 Publication of ZA200603681B publication Critical patent/ZA200603681B/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Virology (AREA)
Diabetes (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Microbiology (AREA)
Mycology (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)

ZA200603681A 2003-11-10 2006-05-09 Interleukin-10 antibodies ZA200603681B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US51899903P	2003-11-10	2003-11-10

Publications (1)

Publication Number	Publication Date
ZA200603681B true ZA200603681B (en)	2010-01-27

Family

ID=34590335

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200603681A ZA200603681B (en)	2003-11-10	2006-05-09	Interleukin-10 antibodies

Country Status (26)

Country	Link
US (5)	US20050101770A1 (xx)
EP (4)	EP1694705B1 (xx)
JP (4)	JP4762148B2 (xx)
KR (3)	KR20120023858A (xx)
CN (2)	CN100595212C (xx)
AR (3)	AR046833A1 (xx)
AT (1)	ATE440867T1 (xx)
AU (2)	AU2004290044B2 (xx)
CA (2)	CA2812856A1 (xx)
CY (1)	CY1110557T1 (xx)
DE (1)	DE602004022855D1 (xx)
DK (1)	DK1694705T3 (xx)
ES (1)	ES2329907T3 (xx)
HK (1)	HK1087722A1 (xx)
HR (1)	HRP20090517T1 (xx)
IL (3)	IL175523A (xx)
NO (1)	NO20062672L (xx)
NZ (1)	NZ546632A (xx)
PE (3)	PE20050925A1 (xx)
PL (1)	PL1694705T3 (xx)
PT (1)	PT1694705E (xx)
RS (1)	RS51180B (xx)
SG (1)	SG155205A1 (xx)
SI (1)	SI1694705T1 (xx)
WO (2)	WO2005047324A2 (xx)
ZA (1)	ZA200603681B (xx)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002220257A1 (en) *	2000-12-07	2002-06-18	Board Of Regents, The University Of Texas System	Methods of treatment involving human mda-7
WO2002057283A1 (en) *	2001-01-19	2002-07-25	Baylor College Of Medecine	Methods and compositions in breast cancer diagnosis and therapeutics
WO2003075952A1 (en) *	2002-03-05	2003-09-18	Board Of Regents, The University Of Texas System	Methods of enhancing immune induction involving mda-7
US8034790B2 (en) *	2003-12-01	2011-10-11	Introgen Therapeutics	Use of MDA-7 to inhibit pathogenic infectious organisms
DE502004006741D1 (de) *	2004-02-23	2008-05-15	Synthes Gmbh	Knochenschraube
US20070281041A1 (en) *	2004-03-02	2007-12-06	Introgen Therapeutics, Inc.	Compositions and Methods Involving MDA-7 for the Treatment of Cancer
WO2006086798A2 (en) *	2005-02-08	2006-08-17	Board Of Regents, The University Of Texas System	Compositions and methods involving mda-7 for the treatment of cancer
US20110104109A1 (en) *	2005-07-13	2011-05-05	Frank Bennett	Tetracyclic indole derivatives and their use for treating or preventing viral infections
WO2007027714A2 (en)	2005-08-31	2007-03-08	Schering Corporation	Engineered anti-il-23 antibodies
WO2007092944A2 (en) *	2006-02-08	2007-08-16	Introgen Therapeutics, Inc.	Compositions and methods involving gene therapy and proteasome modulation
US8063188B2 (en) *	2006-09-05	2011-11-22	Eli Lilly And Company	Anti-myostatin antibodies
JP5059119B2 (ja)	2006-12-14	2012-10-24	シェーリングコーポレイション	操作された抗ｔｓｌｐ抗体
KR20090106539A (ko) *	2006-12-22	2009-10-09	쉐링 코포레이션	Ｈｃｖ 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
WO2008136815A2 (en)	2006-12-22	2008-11-13	Schering Corporation	5, 6-ring annulated indole derivatives and use thereof
SG191442A1 (en)	2006-12-22	2013-07-31	Schering Corp Us	Antibodies to cd200r
MX2009006880A (es)	2006-12-22	2009-07-03	Schering Corp	Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas.
US20100111966A1 (en)	2007-02-23	2010-05-06	Schering Corporation	Engineered anti-il-23p19 antibodies
EP2426144B1 (en)	2007-02-23	2018-10-31	Merck Sharp & Dohme Corp.	Engineered anti-il-23p19 antibodies
NZ579251A (en)	2007-02-28	2012-06-29	Schering Corp	Engineered anti-il-23r antibodies
US8404845B2 (en)	2007-08-29	2013-03-26	Merck Sharp & Dohme Corp.	2,3-substituted azaindole derivatives for treating viral infections
TW200924751A (en) *	2007-08-29	2009-06-16	Schering Corp	2,3-substituted indole derivatives and methods of use thereof
RU2010111551A (ru) *	2007-08-29	2011-10-10	Шеринг Корпорейшн (US)	Замещенные индольные производные и способы их применения
EP2222672B1 (en) *	2007-11-16	2013-12-18	Merck Sharp & Dohme Corp.	3-aminosulfonyl substituted indole derivatives and methods of use thereof
CN102099351A (zh) *	2007-11-16	2011-06-15	先灵公司	3-杂环取代的吲哚衍生物及其使用方法
CN102159579B (zh) *	2008-06-13	2015-03-25	默沙东公司	三环吲哚衍生物及其使用方法
EP2331579B1 (en) *	2008-09-04	2017-07-05	Vet Therapeutics, Inc.	Monoclonal antibodies
SG173654A1 (en) *	2009-02-23	2011-09-29	Glenmark Pharmaceuticals Sa	Humanized antibodies that bind to cd19 and their uses
EP2435424B1 (en)	2009-05-29	2015-01-21	Merck Sharp & Dohme Corp.	Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
KR20170119746A (ko)	2009-09-03	2017-10-27	머크 샤프 앤드 돔 코포레이션	항-ｇｉｔｒ 항체
JP2013512246A (ja)	2009-11-25	2013-04-11	メルク・シャープ・アンド・ドーム・コーポレーション	ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
MX343228B (es) *	2009-11-30	2016-10-26	Biotest Ag	Anticuerpos anti-il-10humanizados para el tratamiento de lupus sistémico eritematoso.
US20130156731A1 (en)	2009-12-22	2013-06-20	Kevin X. Chen	Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
US9433621B2 (en)	2010-02-18	2016-09-06	Merck Sharp & Dohme Corp.	Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CN102918049A (zh)	2010-03-09	2013-02-06	默沙东公司	稠合三环甲硅烷基化合物及其用于治疗病毒性疾病的方法
NZ603581A (en)	2010-06-19	2015-05-29	Sloan Kettering Inst Cancer	Anti-gd2 antibodies
CA2805440A1 (en)	2010-07-26	2012-02-09	Merck Sharp & Dohme Corp.	Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
EP2621279B1 (en)	2010-09-29	2018-04-04	Merck Sharp & Dohme Corp.	Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
EA027256B1 (ru) *	2010-11-23	2017-07-31	Глаксо Груп Лимитед	АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕСЯ С ОНКОСТАТИНОМ М ЧЕЛОВЕКА (hOSM)
CA2981662C (en)	2011-01-14	2019-02-05	The Regents Of The University Of California	Therapeutic antibodies against ror-1 protein and methods for use of same
WO2012142075A1 (en)	2011-04-13	2012-10-18	Merck Sharp & Dohme Corp.	2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2012142085A1 (en)	2011-04-13	2012-10-18	Merck Sharp & Dohme Corp.	2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CN102250243B (zh) *	2011-07-01	2013-08-28	华绍炳	抗白细胞介素-15抗体
WO2013033900A1 (en)	2011-09-08	2013-03-14	Merck Sharp & Dohme Corp.	Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
US20140378416A1 (en)	2011-09-14	2014-12-25	Michael P. Dwyer	Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
US9512405B2 (en)	2011-12-14	2016-12-06	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Non-enzymatic method for isolating human adipose-derived stromal stem cells
WO2014144763A2 (en)	2013-03-15	2014-09-18	Memorial Sloan Kettering Cancer Center	High affinity anti-gd2 antibodies
AR097306A1 (es)	2013-08-20	2016-03-02	Merck Sharp & Dohme	Modulación de la inmunidad tumoral
CN105277638A (zh) *	2014-07-22	2016-01-27	沈鹤霄	一种单克隆抗体IgG质谱测序方法
JO3663B1 (ar)	2014-08-19	2020-08-27	Merck Sharp & Dohme	الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
RU2017145558A (ru)	2015-05-29	2019-07-01	Мерк Шарп И Доум Корп.	Комбинация антагониста pd-1 и олигонуклеотида типа cpg-c для лечения рака
US20180161427A1 (en) *	2015-05-29	2018-06-14	Merck Sharp & Dohme Corp.	Combination of an anti-il-10 antibody and a cpg-c type oligonucleotide for treating cancer
AU2016355570B2 (en)	2015-11-18	2020-01-02	Merck Sharp & Dohme Llc	PD1 and/or LAG3 binders
US11045547B2 (en)	2015-12-16	2021-06-29	Merck Sharp & Dohme Corp.	Anti-LAG3 antibodies and antigen-binding fragments
EP3394099A4 (en) *	2015-12-22	2019-11-27	Merck Sharp & Dohme Corp.	Formulations of Manipulated Anti- IL-10 Antibodies
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
KR20200003107A (ko)	2017-05-02	2020-01-08	머크 샤프 앤드 돔 코포레이션	항-lag3 항체의 제제, 및 항-lag3 항체 및 항-pd-1 항체의 공동-제제
US12023353B2 (en)	2017-10-18	2024-07-02	Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus	Methods and compounds for improved immune cell therapy
US12202894B2 (en) *	2018-03-20	2025-01-21	WuXi Biologics Ireland Limited	Anti-TIM-3 antibodies
IL302871A (en)	2020-11-18	2023-07-01	Astrazeneca Ab	Steroid sparing
CN118043349B (zh) *	2021-06-11	2024-11-15	丰华生物有限公司	一种人源化抗人GPVI单克隆抗体Fab片段及其应用
WO2024091417A1 (en) *	2022-10-24	2024-05-02	Merck Sharp & Dohme Llc	Human hyaluronidase 1 mutants

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL154598B (nl)	1970-11-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en)	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US3939350A (en)	1974-04-29	1976-02-17	Board Of Trustees Of The Leland Stanford Junior University	Fluorescent immunoassay employing total reflection for activation
US3996345A (en)	1974-08-12	1976-12-07	Syva Company	Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en)	1978-04-05	1981-07-07	Syva Company	Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4366241A (en)	1980-08-07	1982-12-28	Syva Company	Concentrating zone method in heterogeneous immunoassays
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0438310A1 (en)	1990-01-19	1991-07-24	Merck & Co. Inc.	Method for producing recombinant immunoglobuline
US6312680B1 (en)	1990-06-29	2001-11-06	Timothy R. Mosmann	Methods of treatment using cytokine synthesis inhibitory factor
JP4124480B2 (ja) *	1991-06-14	2008-07-23	ジェネンテック・インコーポレーテッド	免疫グロブリン変異体
DK0600970T3 (da) *	1991-08-06	2000-05-29	Schering Corp	Anvendelse af interleukin-10-analoger eller -antagonister til behandling af endotoksin- eller superantigeninduceret tokscit
ES2241710T3 (es)	1991-11-25	2005-11-01	Enzon, Inc.	Procedimiento para producir proteinas multivalentes de union a antigeno.
DE69316921T2 (de) *	1992-08-20	1998-06-04	Schering Corp., Kenilworth, N.J.	Neue verwendungen für il-10
DE19529026C2 (de) *	1995-07-28	1997-06-19	Robert Sabat	Monoklonale Antikörper gegen humanes Interleukin-10
US7034121B2 (en) *	2000-01-27	2006-04-25	Genetics Institue, Llc	Antibodies against CTLA4
PE20020574A1 (es) *	2000-12-06	2002-07-02	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido amiloideo beta
EP2298809A3 (en) *	2001-07-12	2012-02-15	FOOTE, Jefferson	Super humanized antibodies
JP4347694B2 (ja) *	2001-10-16	2009-10-21	レイベンバイオテクノロジーズ，インコーポレイティド	癌関連抗原ｃｄ４６に結合する抗体およびその使用方法
US7141653B2 (en) *	2002-03-29	2006-11-28	Schering Corporation	Human monoclonal antibodies to interleukin-5

2004
- 2004-11-08 PE PE2004001085A patent/PE20050925A1/es active IP Right Grant
- 2004-11-08 PE PE2008001585A patent/PE20090047A1/es not_active Application Discontinuation
- 2004-11-08 AR ARP040104114A patent/AR046833A1/es active IP Right Grant
- 2004-11-08 PE PE2008001584A patent/PE20090046A1/es not_active Application Discontinuation
- 2004-11-08 WO PCT/US2004/037013 patent/WO2005047324A2/en unknown
- 2004-11-09 KR KR1020127001612A patent/KR20120023858A/ko not_active Ceased
- 2004-11-09 KR KR1020127001620A patent/KR20120025618A/ko not_active Abandoned
- 2004-11-09 WO PCT/US2004/037518 patent/WO2005047326A2/en active Application Filing
- 2004-11-09 JP JP2006539809A patent/JP4762148B2/ja not_active Expired - Lifetime
- 2004-11-09 DE DE602004022855T patent/DE602004022855D1/de not_active Expired - Lifetime
- 2004-11-09 US US10/985,584 patent/US20050101770A1/en not_active Abandoned
- 2004-11-09 CA CA2812856A patent/CA2812856A1/en not_active Abandoned
- 2004-11-09 CN CN200480040148A patent/CN100595212C/zh not_active Expired - Lifetime
- 2004-11-09 NZ NZ546632A patent/NZ546632A/en not_active IP Right Cessation
- 2004-11-09 EP EP04810674A patent/EP1694705B1/en not_active Expired - Lifetime
- 2004-11-09 CN CN2010100045818A patent/CN102010471A/zh active Pending
- 2004-11-09 PT PT04810674T patent/PT1694705E/pt unknown
- 2004-11-09 AT AT04810674T patent/ATE440867T1/de active
- 2004-11-09 EP EP10013136A patent/EP2292661A3/en not_active Withdrawn
- 2004-11-09 EP EP09010836A patent/EP2128175A1/en not_active Ceased
- 2004-11-09 AU AU2004290044A patent/AU2004290044B2/en not_active Expired
- 2004-11-09 RS RSP-2009/0439A patent/RS51180B/sr unknown
- 2004-11-09 ES ES04810674T patent/ES2329907T3/es not_active Expired - Lifetime
- 2004-11-09 SI SI200431289T patent/SI1694705T1/sl unknown
- 2004-11-09 DK DK04810674T patent/DK1694705T3/da active
- 2004-11-09 EP EP09010835A patent/EP2123678A1/en not_active Withdrawn
- 2004-11-09 CA CA2545255A patent/CA2545255C/en not_active Expired - Lifetime
- 2004-11-09 PL PL04810674T patent/PL1694705T3/pl unknown
- 2004-11-09 SG SG200905318-2A patent/SG155205A1/en unknown
2006
- 2006-05-09 IL IL175523A patent/IL175523A/en active IP Right Grant
- 2006-05-09 ZA ZA200603681A patent/ZA200603681B/xx unknown
- 2006-05-10 KR KR1020067009074A patent/KR101175055B1/ko not_active Expired - Lifetime
- 2006-06-09 NO NO20062672A patent/NO20062672L/no not_active Application Discontinuation
- 2006-09-04 HK HK06109782.7A patent/HK1087722A1/xx not_active IP Right Cessation
2007
- 2007-01-12 US US11/623,006 patent/US7662379B2/en active Active
2009
- 2009-09-25 HR HR20090517T patent/HRP20090517T1/xx unknown
- 2009-10-20 CY CY20091101088T patent/CY1110557T1/el unknown
- 2009-12-10 IL IL202682A patent/IL202682A0/en active IP Right Grant
- 2009-12-10 IL IL202681A patent/IL202681A/en active IP Right Grant
- 2009-12-17 AR ARP090104950A patent/AR074779A2/es unknown
- 2009-12-17 AR ARP090104951A patent/AR074780A2/es not_active Application Discontinuation
2010
- 2010-02-05 US US12/701,386 patent/US8226947B2/en not_active Expired - Lifetime
- 2010-11-30 JP JP2010267846A patent/JP2011062211A/ja not_active Withdrawn
- 2010-11-30 JP JP2010267845A patent/JP2011087590A/ja not_active Withdrawn
2011
- 2011-02-14 AU AU2011200606A patent/AU2011200606B2/en not_active Ceased
2012
- 2012-07-19 US US13/553,554 patent/US8624013B2/en not_active Expired - Lifetime
2013
- 2013-07-24 JP JP2013153356A patent/JP2014014361A/ja not_active Withdrawn
- 2013-12-23 US US14/138,486 patent/US20140112919A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US7662379B2 (en)	2010-02-16
PE20090047A1 (es)	2009-01-26
RS51180B (sr)	2010-10-31
JP2011062211A (ja)	2011-03-31
PE20090046A1 (es)	2009-01-26
EP2292661A2 (en)	2011-03-09
PE20050925A1 (es)	2005-11-29
KR101175055B1 (ko)	2012-08-22
EP1694705B1 (en)	2009-08-26
US20050101770A1 (en)	2005-05-12
AR074779A2 (es)	2011-02-09
HK1087722A1 (en)	2006-10-20
DE602004022855D1 (de)	2009-10-08
US20140112919A1 (en)	2014-04-24
CN1906213A (zh)	2007-01-31
KR20120023858A (ko)	2012-03-13
US8624013B2 (en)	2014-01-07
CY1110557T1 (el)	2015-04-29
JP2011087590A (ja)	2011-05-06
IL202681A (en)	2011-10-31
JP4762148B2 (ja)	2011-08-31
KR20060120093A (ko)	2006-11-24
EP2123678A1 (en)	2009-11-25
WO2005047324A2 (en)	2005-05-26
IL202681A0 (en)	2010-06-30
AU2011200606A1 (en)	2011-03-03
EP2292661A3 (en)	2011-06-22
US8226947B2 (en)	2012-07-24
NZ546632A (en)	2009-07-31
DK1694705T3 (da)	2009-12-07
SI1694705T1 (sl)	2010-01-29
IL202682A0 (en)	2010-06-30
PT1694705E (pt)	2009-11-30
AU2004290044B2 (en)	2010-11-18
ATE440867T1 (de)	2009-09-15
SG155205A1 (en)	2009-09-30
AU2011200606B2 (en)	2012-05-10
ES2329907T3 (es)	2009-12-02
CA2812856A1 (en)	2005-05-26
US20100203049A1 (en)	2010-08-12
JP2008500020A (ja)	2008-01-10
WO2005047326A3 (en)	2005-12-22
US20120282253A1 (en)	2012-11-08
CA2545255C (en)	2013-06-25
NO20062672L (no)	2006-06-09
AR074780A2 (es)	2011-02-09
KR20120025618A (ko)	2012-03-15
AU2004290044A1 (en)	2005-05-26
JP2014014361A (ja)	2014-01-30
IL175523A (en)	2011-01-31
CN100595212C (zh)	2010-03-24
PL1694705T3 (pl)	2010-02-26
EP1694705A2 (en)	2006-08-30
CA2545255A1 (en)	2006-05-05
CN102010471A (zh)	2011-04-13
EP2128175A1 (en)	2009-12-02
AR046833A1 (es)	2005-12-28
IL175523A0 (en)	2006-09-05
HRP20090517T1 (en)	2009-10-31
WO2005047326A2 (en)	2005-05-26
US20070178097A1 (en)	2007-08-02

Publication	Publication Date	Title
IL175523A0 (en)	2006-09-05	Interleukin-10 antibodies
EP1616881A4 (en)	2008-08-27	ANTI-MPL ANTIBODIES
IL175608A0 (en)	2006-09-05	Antibodies
EP1494693A4 (en)	2006-08-02	SPECIFIC ANTIBODIES TO CRIPTO
PL375405A1 (en)	2005-11-28	Antibodies
EP1648512A4 (en)	2009-01-21	ANTI-CD19 ANTIBODIES
IL173557A0 (en)	2006-07-05	Variable antibodies
PT1599504E (pt)	2015-03-02	Anticorpo modificado
GB0306618D0 (en)	2003-04-30	Antibody
IL172511A0 (en)	2006-04-10	Specific human antibodies
GB0226878D0 (en)	2002-12-24	Antibodies
GB0302699D0 (en)	2003-03-12	Immunoglobulin
GB0311108D0 (en)	2003-06-18	Proteins
GB0329711D0 (en)	2004-01-28	Antibodies
GB0317974D0 (en)	2003-09-03	Novel antibodies
GB0210508D0 (en)	2002-06-19	Antibodies
GB0218232D0 (en)	2002-09-11	Antibodies
GB0218229D0 (en)	2002-09-11	Antibodies
GB0218230D0 (en)	2002-09-11	Antibodies
GB0203018D0 (en)	2002-03-27	Antibodies
GB0218234D0 (en)	2002-09-11	Antibodies
GB0218235D0 (en)	2002-09-11	Antibodies
HK1072381A1 (en)	2005-08-26	Cripto-specific antibodies cripto-specific
GB0217742D0 (en)	2002-09-11	Novel antibodies
HK1209139A1 (en)	2016-03-24	Modified antibody